Application‑based segmentation of the Aspirin Effervescent Tablets market isolates four principal therapeutic uses, each mapping to a distinct revenue channel. Analgesic use, encompassing headache, musculoskeletal pain, and minor injury relief, remains the largest driver, accounting for roughly 45 % of sales; its breadth is reinforced by over‑the‑counter availability and high consumer turnover. Cardiovascular prophylaxis, where low‑dose effervescent aspirin is prescribed to reduce thrombotic events, contributes about 30 % of the market, reflecting expanding guideline endorsement for primary and secondary prevention. Anti‑inflammatory application, targeting conditions such as rheumatoid arthritis and acute gout flares, secures an estimated 15 % share, limited by the need for higher dosages and associated gastrointestinal risk management. Antipyretic use, primarily for fever reduction in viral infections, occupies the remaining 10 % of market volume, a segment that experiences seasonal fluctuations. These application categories collectively shape the market taxonomy, and their relative weights are visualized in the accompanying pie‑chart, guiding strategic allocation of R&D and marketing resources.
